Conditional approval extended through December 2026 for the treatment of CID in dogs CID confirmatory effectiveness trial ...
Jaguar’s requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia® A ...
Company's Canalevia ®-CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive ...
SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”), under its Jaguar Animal Health tradename for the veterinary market, today announced it is ...
Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally SAN FRANCISCO, ...
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX) ("Jaguar" or the "Company ...
TipRanks on MSN
Jaguar Health executes strategic stock exchange agreements
Jaguar Animal Health ( ($JAGX) ) has shared an update. On June 27, 2025, Jaguar Health, Inc. engaged in a transaction with Iliad Research and ...
SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Animal Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), an animal health company focused on developing and commercializing first-in-class gastrointestinal ...
Jaguar Animal Health ( ($JAGX) ) has shared an announcement. On December 8, 2025, Jaguar Health held a Special Meeting where stockholders approved ...
SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced it is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback